中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

23 records (took 0.022 seconds)

    SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT
    12.
    发明申请
    SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT 审中-公开

    公开(公告)号：US20200231593A1

    公开(公告)日：2020-07-23

    申请号：US16843729

    申请日：2020-04-08

    Applicant: AbbVie Inc.

    Inventor： Nathaniel Catron ,  Shuang Chen ,  Yuchuan Gong ,  Geoff G. Zhang

    IPC: C07D471/04

    Abstract: Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

    SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT
    13.
    发明申请
    SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT 审中-公开

    公开(公告)号：US20190194196A1

    公开(公告)日：2019-06-27

    申请号：US16288324

    申请日：2019-02-28

    Applicant: AbbVie Inc.

    Inventor： Nathaniel Catron ,  Shuang Chen ,  Yuchuan Gong ,  Geoff G. Zhang

    IPC: C07D471/04

    CPC classification number: C07D471/04

    Abstract: Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

    Salts and crystalline forms of an apoptosis-inducing agent
    14.
    发明授权
    Salts and crystalline forms of an apoptosis-inducing agent 有权

    公开(公告)号：US09840502B2

    公开(公告)日：2017-12-12

    申请号：US14957097

    申请日：2015-12-02

    Applicant: AbbVie Inc.

    Inventor： Nathaniel Catron ,  Shuang Chen ,  Yuchuan Gong ,  Geoff G. Zhang

    IPC: C07D471/04

    CPC classification number: C07D471/04

    Abstract: Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

    Crystal Forms
    16.
    发明申请
    Crystal Forms 有权
    水晶表格

    公开(公告)号：US20150353600A1

    公开(公告)日：2015-12-10

    申请号：US14731765

    申请日：2015-06-05

    Applicant: AbbVie Inc.

    Inventor： Shuang Chen ,  Bradley D. Gates ,  Ahmad Y. Sheikh

    IPC: C07K5/10

    CPC classification number: A61K9/08 ,  A61K9/10 ,  A61K38/06 ,  A61K47/32 ,  C07K5/0808 ,  C07K5/0827 ,  C07K5/10

    Abstract: The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of FIGS. 1-4.

    Abstract translation: 本发明的特征在于化合物I的结晶形式。在一个实施方案中，化合物I的结晶形式在PXRD图案中具有特征峰，如图1和图2中任一项所示。 1-4。

    Azaadamantane formate ester and process for preparing azaadamantane derivatives
    17.
    发明授权
    Azaadamantane formate ester and process for preparing azaadamantane derivatives 有权
    氮杂金刚烷甲酸酯和制备氮杂金刚烷衍生物的方法

    公开(公告)号：US08969562B2

    公开(公告)日：2015-03-03

    申请号：US14204356

    申请日：2014-03-11

    Applicant: AbbVie Inc.

    Inventor： Albert Wayne Kruger ,  Shuang Chen ,  Steven Cramer Cullen ,  James Joseph Napier

    IPC: C07D285/135 ,  C07D285/12 ,  C07D471/18 ,  C07C249/02

    CPC classification number: C07D471/18 ,  C07C249/02 ,  C07D285/12 ,  C07D285/135

    Abstract: A compound, (4s)-1-azaadamantane-4yl formate ester, is described. In addition, a process is described for preparing (4s)-1-azaadamantane-4yl formate ester, aminothiadiazole-phenyl phosphate salt, bromothiadizole-phenyl or (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.13,7]-decane dihydrogen citrate. Furthermore, a process is described, comprising step of hydrolyzing (4s)-1-azaadamantane-4yl formate ester to form (4s)-1-azaadamantan-4-ol HBr salt.

    Abstract translation: 描述了化合物（4s）-1-氮杂金刚烷-4-基甲酸酯。 此外，描述了制备（4s）-1-氮杂金刚烷-4-基甲酸酯，氨基噻二唑 - 苯基磷酸盐，溴噻嗪 - 苯基或（4s）-4-（5-苯基-1,3,4-噻二唑-2-基） 吡啶-2-基氧基）-1-氮杂三环[3.3.1.13.7] - 十二烷基二氢柠檬酸盐。 此外，描述了包括水解（4s）-1-氮杂金刚烷-4-基甲酸酯以形成（4s）-1-氮杂金刚烷-4-醇HBr盐的步骤。

Patent Agency Ranking